163.98
-1.43 (-0.86%)
| Previous Close | 165.41 |
| Open | 165.56 |
| Volume | 733,699 |
| Avg. Volume (3M) | 1,209,662 |
| Market Cap | 9,964,263,424 |
| Price / Earnings (Forward) | 8.52 |
| Price / Sales | 2.43 |
| Price / Book | 2.54 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | 11.86% |
| Operating Margin (TTM) | -2.90% |
| Diluted EPS (TTM) | 7.37 |
| Quarterly Revenue Growth (YOY) | -0.50% |
| Quarterly Earnings Growth (YOY) | 103.00% |
| Total Debt/Equity (MRQ) | 129.82% |
| Current Ratio (MRQ) | 3.38 |
| Operating Cash Flow (TTM) | 1.56 B |
| Levered Free Cash Flow (TTM) | 1.50 B |
| Return on Assets (TTM) | 3.99% |
| Return on Equity (TTM) | 12.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Jazz Pharmaceuticals plc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.04% |
| % Held by Institutions | 101.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Goldentree Asset Management Lp | 30 Sep 2025 | 1,137,106 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 247.00 (B of A Securities, 50.63%) | Buy |
| Median | 224.50 (36.91%) | |
| Low | 188.00 (UBS, 14.65%) | Hold |
| Average | 221.00 (34.77%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 173.11 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 12 Jan 2026 | 235.00 (43.31%) | Buy | 163.68 |
| Truist Securities | 12 Jan 2026 | 230.00 (40.26%) | Buy | 163.68 |
| Piper Sandler | 10 Dec 2025 | 219.00 (33.55%) | Buy | 164.97 |
| UBS | 24 Nov 2025 | 188.00 (14.65%) | Hold | 180.90 |
| B of A Securities | 18 Nov 2025 | 247.00 (50.63%) | Buy | 180.52 |
| Baird | 18 Nov 2025 | 209.00 (27.45%) | Buy | 180.52 |
| Wells Fargo | 18 Nov 2025 | 235.00 (43.31%) | Buy | 180.52 |
| Morgan Stanley | 17 Nov 2025 | 205.00 (25.02%) | Buy | 170.09 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |